PubRank

Ipilimumab With or Without Dabrafenib, Trametinib, and/or Nivolumab in Treating Patients With Melanoma That Is Metastatic or Cannot Be Removed by Surgery

Clinical Trial ID NCT01940809

PubWeight™ 17.51‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01940809

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. J Clin Oncol 2014 1.47
2 Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma. Oncotarget 2014 1.33
3 Combining immunotherapy with oncogene-targeted therapy: a new road for melanoma treatment. Front Immunol 2015 1.04
4 Cancer immunotherapy in clinical practice -- the past, present, and future. Chin J Cancer 2014 0.98
5 Cytotoxic T lymphocyte antigen-4 and immune checkpoint blockade. J Clin Invest 2015 0.98
6 Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma. Mol Cancer Ther 2014 0.92
7 Updates in Therapy for Advanced Melanoma. Cancers (Basel) 2016 0.91
8 Combination therapies for the treatment of advanced melanoma: a review of current evidence. Biochem Res Int 2014 0.86
9 Small molecule drugs with immunomodulatory effects in cancer. Hum Vaccin Immunother 2015 0.86
10 Understanding the biology of melanoma and therapeutic implications. Hematol Oncol Clin North Am 2014 0.85
11 Immune Effects of Chemotherapy, Radiation, and Targeted Therapy and Opportunities for Combination With Immunotherapy. Semin Oncol 2015 0.82
12 Oncogene withdrawal engages the immune system to induce sustained cancer regression. J Immunother Cancer 2014 0.80
13 Combining targeted therapy with immunotherapy. Can 1+1 equal more than 2? Semin Immunol 2016 0.78
14 Long-term survival as a treatment benchmark in melanoma: latest results and clinical implications. Ther Adv Med Oncol 2015 0.78
15 New developments in the treatment of metastatic melanoma - role of dabrafenib-trametinib combination therapy. Drug Healthc Patient Saf 2014 0.77
16 Preclinical exploration of combining plasmacytoid and myeloid dendritic cell vaccination with BRAF inhibition. J Transl Med 2016 0.76
17 Ipilimumab (Anti-Ctla-4 Mab) in the treatment of metastatic melanoma: Effectiveness and toxicity management. Hum Vaccin Immunother 2016 0.75
18 Raising the bar: optimizing combinations of targeted therapy and immunotherapy. Ann Transl Med 2015 0.75
19 CCR 20th Anniversary Commentary: MAPK/ERK Pathway Inhibition in Melanoma-Kinase Inhibition Redux. Clin Cancer Res 2015 0.75
20 The Role of Adaptive Immunity in the Efficacy of Targeted Cancer Therapies. Trends Immunol 2016 0.75
Next 100